Blood Flow Monitor Could Save NHS £400m

March 31st, 2011

A British invention, the Blood Flow Monitor, has been highlighted as reducing complications and speeding up recovery.  NICE – the National Institute for Health and Clinical Excellence – has indicated that if 50% of eligible patients were monitored using the device then it would save the NHS more than £400 million a year.  Currently it is only used in 3% of eligible patients.

The BBC’s Fergus Walsh interviewed Professor Monty Mythen, an anaesthetist from University College London, about the device.  The following is a transcript of the interview:

So Professor, can you explain how this works, very simply?

Here we have a pipe which has been specially modified.  We pass this into the patient.  This (one end) is the monitoring end.  We pass it in through the mouth and then feed it gently down into the gullet.  Our aim is for it to sit within the gullet, directly adjacent to the aorta, which is the main pipe which flows out from the heart.

And what does it pick up when its there?

It uses ultrasound to measure the speed of blood flowing out from the heart.

and you have got this actually operating here?

We have got it operating here at the moment. So what we have here is the trace. On one axis we have speed, across the bottom we have time. So the area under that curve is distance.

Blood Flow Monitor

Blood Flow Monitor, Image credit: BBC

Very simply, how does that help you and the patient during the operation?

Well by being able to look directly at each beat of the heart and the amount of blood that is flowing out from it, we can adjust the amount of – particularly – fluid we give to the patient to make that the optimal size.

And does that then lead to less complications?

That results in improved delivery of oxygen and nutrients to the tissues and that avoids complications in the long run.

And does that actually save lives?

There is evidence to suggest that this also saves lives.

Surgery

I can see there is a huge bank of monitors here already, why do you need something extra?

We need something because most of these monitors do not measure directly the flow from the heart.  So, the flow carries the oxygen and nutrients to the cell.  That is the main thing that we are interested in.  Traditionally what we have done is measure pressure as a way to try to gauge that.

Blood Pressure

Blood Pressure. img credit BBC

And any side effects for patients?

There are no risks associated with the use of this (blood flow monitor) that have been identified in the fifteen years that we have used it.  Occasionally, a minor sore throat, but nothing compare to the invasive monitors that we have used in the past.

Breast Cancer Advances Could Impact within 12 Months

March 28th, 2011

Harvard has released details of its study into triple-negative breast cancer and potential advances which may impact treatement of the disease in as little as 12 months.

The study identified how a particular enzyme (PTPN12) fails to function in 60% of triple negative breast cancers. The absence of these enzymes can cause normal breast cells to become cancerous.  The team identified 3 enzymes that were activated when the enzyme PTPN12 was ’switched off’.  The study suggests that these three enzymes, when activated improperly by the lack of the PTPN12, could be a major cause of triple negative breast cancer.  The trials in mice looked at how they could ‘turn off’ these three enzymes.

The Harvard team used two currently available cancer drugs to treat mice with triple negative breast cancer.  These drugs targeted the three enzymes.  By using one drug which worked on two of the three enzymes (Tykerb) tumours shrank by 80%.  When combined with another cancer drug (Sutent), which targets the third enzyme, the tumorus shrank by more than 90% and the life expectancy ‘more than doubled’.

Breast cancer cell image (photo credit: guardian.co.uk)

The results suggest that the two drugs used in tandem could provide a therapy for those with triple-negative breast cancer.  In the UK, both of these drugs have NICE guidance for certain conditions under certain circumstances.

The Harvard team will now launch a phase 2 trial by the beginning of 2012.

What is triple negative breast cancer?

Triple negative breast cancer is an aggressive disease with few options for treatment.  Chemotherapy is currently the method of treating the tumours and if it spreads there is an average survival rate of 1 year.  It is when the breast cancer cells test negative for oestrogen, progesterone and HER2 receptors.  This means that the cancer’s growth is not likely to be ‘fuelled by oestrogen or progesterone or by growth signals from the HER2 protein’ and does not respond to hormonal therapies or those that target the HER2 receptors.  The latter would include the much written-about drug Herceptin.  However, other drugs and drug combinations can be used to treat triple negative breast cancer.

According to Cancer Research UK, 15% of breast cancers are triple negative.

Read Freedom Healthnet’s news pages for more information and news about medical insurance, health matters and the NHS.

NICE rejects further Cancer Drugs

March 14th, 2011

Following along from earlier reports of NICE’s rejection of cancer drugs, NICE has recommended that Tarceva and Javlor should also not be funded on the NHS.

Tarceva (Erlotinib) is a drug for terminal lung cancer patients that is reported to give a better quality of life and to prolong the effects of chemotherapy.  NICE has rejected this based upon the uncertainty about how much benefit it actually gives to patients.  The manufacturer indicates that this extends life by 3 months, but a previously-approved drug (pemetrexed) offers a potential 5.2 months and the recommendation by NICE is to continue with this drug.

The second drug, Javlor (Vinfunine) is designed for treatment of advanced metastatic bladder cancer.  NICE has rejected this drug on the basis of lack of conclusive evidence.

At present these recommendations are not final and local NHS trusts can make their own decisions.

Freedom Healthnet covers NICE approved drugs.  Read full details of its health insurance and cancer policy.

NICE, Cancer Drugs & Health Insurance

February 22nd, 2011

Health Insurance can cover cancer (see Freedom Healthnet’s Cancer Cover Guide).  However, as with treatment via the NHS, only NICE drugs are covered by Freedom.

NICE (National institute for Health and Clinical Excellence) has issued guidance that Avastin should not be funded for the treatment of metastatic breast cancer.  It has approved the use of two new cancer drugs:  Pazopanib (Votrient) and Bendamustine (Levact).

Avastin (Bevacizumab)’s licence has been rescinded in the USA by the United States Food and Drug Administration (Dec 10) because of concerns over efficacy.  NICE looked at the evidence for using the drug in combination with a chemotherapy drug in patients whose breast cancer had spread to other parts of the body.  NICE concluded that the the drug did not prove that a patient’s life would be extended and that it didn’t offer a better quality of life than existing treatments.  Therefore it has advised that the NHS should not fund Avastin.

Pazopanib is used in the treatment of advanced kidney cancer and information indicates that it can delay the progression of the cancer by about 8 months.  This has been approved by NICE.

Bendamustine has had fast-track approval from NICE as it has evidence that it can slow the growth and spread of chronic lymphocytic leukaemia by on average 13 months more than the current alternative drugs.  This has been approved by NICE.

NICE Approves Blood Cancer Drug Vidaza

February 18th, 2011

NICE (The National Institute for Health and Clinical Excellence) has approved the use of the drug Vidaza in the treatment of rare blood cancers.

Previously NICE, the organisation that controls which drugs can be used on the NHS, had stated that the NHS should not fund this drug. But, after drug manufacturer Celgene offered discounted costs, NICE approved its use via the NHS.  It now recommends that Vidaza (Azacitidine) should be available to NHS patients suffering from bone marrow disorders who cannot undergo a stem cell transplantation.  The drug is said to have the potential to extend the lives of patients suffering from myelodysplastic syndromes by an average of 9 months.

Myelogysplastic syndromes are a group of bone marrow disorders where the marrow doesnt produce enough of one or more types of blood cells.  Draft guidance has been issued to the NHS by NICE and currently it is at the discretion of the local NHS trusts as to whether or not to fund the drug.

Government £50 million Funding Boost for Cancer Drugs

July 27th, 2010

The government has announced a £50 million injection of capital to pay for new cancer drugs for very sick patients.  From October this year, doctors in England will be able to offer cancer drugs that have not been approved by NICE.

The move from the coalition government comes in response to the news that the UK lags behind many developed countries in providing the latest cancer drugs to its cancer sufferers.  Health secretary Andrew Lansley commented “I promised that I would help patients in England get cancer drugs that are readily available in the rest of Europe.”

The report, from government cancer Tsar Professor Sir Mike Richards, also looked at drug use for other diseases cuch as heart disease, dementia and arthritis.   He also indicated that this increased access to a wider range of latest drugs would not improve survival rates.

What could this mean for people who hold private health insurance policies?    Currently, most insurers look to NICE for guidance on approval for drugs for private medical treatment.  Insurers will probably continue to do so but will be considering the government initiative.